Excessive Daytime Sleepiness
📧 Sign up to get email alerts when something new happens for Excessive Daytime Sleepiness.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia [Phase 3]
A completed Phase 3 long-term study assessing the safety and effectiveness of pitolisant in adult patients with idiopathic hypersomnia, incl…
-
CLINICAL_TRIALS trial_result · 2025-11-13Clinical Trial Update: A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) [Phase 3]
A Phase 3 study (ENCORE) evaluating the long-term efficacy and safety of AXS-12 (reboxetine) in narcolepsy with cataplexy and excessive dayt…
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: Characterization of Children with Complaints of Excessive Daytime Sleepiness
This clinical trial update characterizes children presenting with excessive daytime sleepiness and notes that the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-03Clinical Trial Update: A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA) [Phase 3]
This clinical trial update describes a Phase 3, double-blind, placebo-controlled study evaluating solriamfetol for excessive daytime sleepin…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: Analysis of New Salivary Biomarkers to Evaluate Excessive Diurnal Sleepiness in Children With Hypersomnia
This completed clinical trial analyzed salivary biomarkers to evaluate excessive daytime sleepiness in children with hypersomnia. The study …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSA [Phase 3]
Phase 3 clinical trial evaluating pitolisant for excessive daytime sleepiness in obstructive sleep apnea patients has completed.
-
CLINICAL_TRIALS trial_result · 2022-08-12Clinical Trial Update: Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy [Phase 2]
Phase 2 study evaluating safety and efficacy of mazindol extended release (NLS-2) for narcolepsy and related daytime sleepiness has complete…
-
CLINICAL_TRIALS trial_result · 2022-03-22Clinical Trial Update: Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy [Phase 3]
Phase 3 trial update for once-nightly sodium oxybate in narcolepsy assessing excessive daytime sleepiness and cataplexy completed with poste…
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy [Phase 2]
Phase 2 clinical trial evaluating the effects of JZP-110 on driving performance in adults with narcolepsy and excessive daytime sleepiness h…
-
CLINICAL_TRIALS trial_result · 2020-11-24Clinical Trial Update: BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness [Phase 2]
Phase 2 trial of BEN-2001 in Parkinson's disease patients with excessive daytime sleepiness has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2020-07-08Clinical Trial Update: Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA [Phase 3]
Phase 3 trial evaluating pitolisant (BF2.649) for excessive daytime sleepiness in obstructive sleep apnea has completed.
-
CLINICAL_TRIALS trial_result · 2020-01-09Clinical Trial Update: A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness [Phase 2]
Phase 2 trial update on JZP-110 for Parkinson's disease with excessive daytime sleepiness assessing safety, efficacy, and pharmacokinetics.
-
CLINICAL_TRIALS trial_result · 2017-03-24Clinical Trial Update: Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia [Phase 2, Phase 3]
A cross-over study evaluated armodafinil for daytime sleepiness associated with treated nocturia; the trial completed and results were poste…
-
CLINICAL_TRIALS trial_result · 2015-05-29Clinical Trial Update: A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics [Phase 1]
Phase 1, single-dose study of JZP-386 to evaluate safety, pharmacokinetics and pharmacodynamics has completed, sponsored by Concert Pharmace…
-
CLINICAL_TRIALS trial_result · 2015-01-21Clinical Trial Update: BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS [Phase 3]
Phase 3 clinical trial update for BF2.649 in obstructive sleep apnea patients on CPAP who still report excessive daytime sleepiness; the stu…
-
CLINICAL_TRIALS trial_result · 2015-01-21Clinical Trial Update: BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP. [Phase 3]
Phase 3 trial update shows BF2.649 investigated in obstructive sleep apnea patients with excessive daytime sleepiness who refuse CPAP; the s…
-
CLINICAL_TRIALS trial_result · 2013-02-11Clinical Trial Update: Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy [Phase 3]
Phase 3 study evaluating BF2.649 with add-on Modafinil for cataplexy in narcolepsy has completed, reporting efficacy and safety findings.
-
CLINICAL_TRIALS trial_result · 2012-06-15Clinical Trial Update: Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) [Phase 2]
Phase 2 dose-range finding study of BF2.649 in obstructive sleep apnea completed, evaluating effects on excessive daytime sleepiness.
-
CLINICAL_TRIALS trial_result · 2012-06-11Clinical Trial Update: Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy [Phase 3]
Phase 3 trial evaluating BF2.649 for excessive daytime sleepiness in narcolepsy has completed, assessing efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2012-06-11Clinical Trial Update: Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients [Phase 2]
Phase 2 dose-range study evaluating BF2.649 versus placebo in Parkinson's disease patients with excessive daytime sleepiness has completed.
-
CLINICAL_TRIALS trial_result · 2010-07-08Clinical Trial Update: Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder [Phase 3]
A Phase 3 study evaluated armodafinil for excessive sleepiness in healthy subjects with jet lag disorder; results have been posted.
-
CLINICAL_TRIALS trial_result · 2010-03-31Clinical Trial Update: Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness [Phase 3]
Extension Phase 3 study of armodafinil for excessive daytime sleepiness, including narcolepsy and related sleep disorders, completed with re…
-
CLINICAL_TRIALS trial_result · 2009-09-23Clinical Trial Update: Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD [Phase 3]
A Phase 3 trial evaluating armodafinil (CEP-10953) for excessive daytime sleepiness in shift work sleep disorder has completed and results w…